MoFo News Item

MoFo Advises Cordlife Group on Proposed Disposal of Shares and Convertible Note Issued by China Cord Blood Corporation

11 May 2015

Morrison & Foerster is advising Cordlife Group Limited (“Cordlife”), a Singapore listed company, on its sale to Golden Meditech Holdings Limited (“Golden Meditech”), a Hong Kong listed company, of 7,314,015 ordinary shares of par value US$0.0001 per share in China Cord Blood Corporation (“CCBC”), a Cayman Islands company listed on the New York Stock Exchange, and a 7% senior unsecured convertible note due 3 October 2017 issued by CCBC to Cordlife. Please refer to Cordlife’s press release for full details of the transaction.

The deal team was led by Singapore corporate partner Shirin Tang and San Francisco corporate partner Michael O'Bryan.

Additional team members include Washington, D.C. corporate associate Rose Zukin and Tokyo corporate associate Matthew Longarini.

About Cordlife Group Limited (Bloomberg stock code: CLGL SP)
Incorporated in May 2001, Cordlife Group Limited is a multi-product healthcare company catering to the mother and child segment and a leading cord blood and umbilical cord lining banking services provider. Today, Cordlife operates the largest private cord blood banks in each of Singapore, the Philippines and Indonesia, and is amongst the top three market leaders in Hong Kong and India. Cordlife also holds approximately 10.02% and 31.81% stakes in China Cord Blood Corporation and StemLife Berhad respectively, both of which are their countries’ largest cord blood bank operators. For more information, please visit our website at http://www.cordlife.com.

About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.

About Golden Meditech Holdings Limited
Golden Meditech Holdings Limited is China’s leading integrated healthcare device and service operator, and first medical device enterprise that was publicly listed outside of China on the Hong Kong Stock Exchange. It is involved in five (5) different businesses, namely (a) the medical device business, (b) the cord blood banking business, which is listed, through its subsidiary, China Cord Blood Corporation, (c) the hospital management business, (d) the medical insurance administration business, and (e) the Chinese herbal medicine business. For more information, please visit our website at http://www.goldenmeditech.com.

Close

Feedback

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.